Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +48.11%
#2 Pons Pons +36.58%
#3 Purr Purr +30.54%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.71%
#5 StonkBroker StonkBroker +27.42%
#6 TENDIES TENDIES +27.29%
#7 Starpower Starpower +27.21%
#8 Magma Finance Magma Finance +26.82%
#9 SkyAI SkyAI +24.81%
#10 PondCoin PondCoin +22.22%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
설정
언어
한국어
통화
USD
테마
Sofiva Genomics Co.,Ltd. Sofiva Genomics Co.,Ltd.

Sofiva Genomics Co.,Ltd.

6615
주식 순위 #29072
Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan,... Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expectant parents, individuals with inherited conditions, and their families. Their extensive prenatal diagnostics include screenings for conditions such as thalassemia carrier status, various microdeletion syndromes, single-gene abnormalities, common chromosomal anomalies, and specific skeletal dysplasia mutations. They also provide multi-gene panel testing for inherited diseases, folate metabolism genetic analysis, carrier screening for spinal muscular atrophy (SMA) and Fragile X syndrome, congenital infection detection, preeclampsia risk assessment, maternal serum screening for Down syndrome, and karyotyping. Within the oncology sector, Sofiva Genomics delivers advanced cancer screenings, dynamic monitoring of tumor activity, and genetic evaluations for hereditary cancer predisposition. This includes specialized panels for women's cancers (breast, colon, ovarian, and endometrial), alongside human papillomavirus (HPV) screening. Furthermore, the company conducts genetic testing for rare diseases and provides specialized reproductive services such as preimplantation genetic diagnosis (PGD) and next-generation sequencing (NGS)-based preimplantation genetic screening (PGS). For newborns, their services encompass comprehensive "baby scans," screenings for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome (CCHS), congenital cytomegalovirus (CMV) infection, and genetic risk assessment for atopic dermatitis. Beyond these specialized offerings, Sofiva Genomics also performs biochemical and chromosomal analyses, complemented by valuable advisory and support services for its clientele.
주가
$1.07
시가총액
$23.11M
변동 (1일)
0.00%
변동 (1년)
4.66%
국가
TW
거래 Sofiva Genomics Co.,Ltd. (6615)

카테고리

Healthcare
Sofiva Genomics Co.,Ltd. (6615)의 P/E 비율
2026 기준 P/E 비율 TTM: 0
Sofiva Genomics Co.,Ltd.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 0입니다. 2026년 말 기준 P/E 비율은 0였습니다.
Sofiva Genomics Co.,Ltd.의 P/E 비율 기록 (2026 ~ 2026)
매년 말 P/E 비율
연도 P/E 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/E 비율
회사 P/E 비율 P/E 비율 차이 국가
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 31.59 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 35.83 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -227.89 -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 38.69 -
US
P/E 비율 읽는 방법

P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.

P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.

양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.